WORCESTER, Mass.–(BUSINESS WIRE)–RXi Pharmaceuticals Corporation (Nasdaq: RXII) today reported its financial results for the third quarter ended September 30, 2010. RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both…